Management of Polypharmacy and Potential Drug–Drug Interactions in Patients with Mycobacterial Infection: A 1-Year Experience of a Multidisciplinary Outpatient Clinic

In 2022, we opened an outpatient clinic for the management of polypharmacy and potential drug–drug interactions (pDDIs) in patients with mycobacterial infection (called GAP-MyTB). All who underwent a GAP-MyTB visit from March 2022 to 2023 were included this retrospective analysis. Fifty-two database. They given 10.4 ± 3.7 drugs (2.8 1.0 7.8 3.9 were, respectively, antimycobacterial agents co-medications). Overall, 262 pDDIs identified classified as red-flag (2%), orange-flag (72%), or yellow-flag (26%) types. The most frequent actions suggested after assessment perform ECG (52%), therapeutic drug monitoring (TDM, 40%), electrolyte (33%) among diagnostic interventions reduce/stop proton pump inhibitors (37%), reduce/change statins (14%), reduce anticholinergic burden (8%) pharmacologic interventions. TDM rifampicin revealed suboptimal exposure 39% that resulted TDM-guided dose increment (from 645 101 793 189 mg/day, p < 0.001). high prevalence risk highlights need ongoing education on prescribing principles optimal individual patients. A multidisciplinary approach involving physicians clinical pharmacologists could help achieve goal.